Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma

Patients with advanced intrahepatic cholangiocarcinoma (iCCA) often have a poor prognosis. Recent advancements in targeted molecular therapy and immunotherapy have been made. Herein, we report a case of advanced iCCA treated with a combination of pemigatinib (a selective FGFR inhibitor), chemotherap...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhuochao, Wang, Gaofei, Du, Lei, Zhao, Jie, Pan, Lichao, Zhang, Gong, Wang, Fei, Liu, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10245386/
https://www.ncbi.nlm.nih.gov/pubmed/37292215
http://dx.doi.org/10.3389/fimmu.2023.1124482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10245386/
https://www.ncbi.nlm.nih.gov/pubmed/37292215
http://dx.doi.org/10.3389/fimmu.2023.1124482

Ejemplares similares